Today's Stock Movers: GE Vernova, Constellation Energy, Micron, AST SpaceMobile, Novo Nordisk, and More -- Barrons.com

Dow Jones
01/17

By Mackenzie Tatananni, George Glover, Joe Woelfel, and Connor Smith

Stocks ticked lower Friday as the market absorbed President Donald Trump's latest comments on geopolitical tensions and the Federal Reserve.

These stocks made moves:

Micron Technology jumped 7.8%. Board member Mark Liu snapped up $7.8 million worth of shares, according to a securities filing. Purchases by corporate insiders tend to signal conviction in a company's growth story -- and that's particularly notable given how well Micron has performed lately. The stock has risen 237% in 12 months, thanks to stellar earnings that reflected sky-high demand for flash memory chips.

Memory-chip maker Sandisk traded rose 1.1%. Shares closed up 5.5% on Thursday after two analysts hiked their price targets.

Hard-drive maker Western Digital, which spun off Sandisk in February 2025, fell 0.3%, while peer Seagate Technology added 1.9%.

GE Vernova advanced 6.1%. The Trump administration is pushing PJM, the nation's largest electricity grid operator, to hold a special auction to supply data centers. Trump on Friday signed an agreement with several governors from states in the mid-Atlantic region to encourage the construction of power plants.

Shares in Constellation Energy and Vistra, the owners of existing plants, sank 9.8% and 7,5%, respectively.

AST SpaceMobile soared 14%, extending gains from the previous session when it advanced 6.3%. The satellite-communications company was selected as one of the eligible vendors to the U.S. Missile Defence Agency, in the latest tranche of awards for its SHIELD program.

Mosaic tumbled 4.5%. In an earnings pre-announcement, the chemical company said fourth-quarter fertilizer demand had fallen well beyond normal seasonal softness. Mosaic expects phosphate sales volumes of 1.3 million tons and potash sales volumes of 2.2 million tons.

U.S.-listed shares of Novo Nordisk climbed 9.1%. The drugmaker secured approval for a higher dose of its blockbuster weight-loss treatment in the U.K. The Medicines and Healthcare Products Regulatory Agency approved a maximum dose of up to 7.2 milligrams per week of Wegovy, a step up from the previous 2.4 mg limit.

ImmunityBio surged 40% after spiking 31% in Thursday's session. The biotech company expects full-year revenue from its bladder cancer drug Anktiva to surge 700% year over year to $113 million. Earlier this week, Immunitybio said the Saudi Food and Drug Authority had approved Anktiva for the treatment of patients with non-small cell lung cancer.

State Street declined 6.1%. The bank posted lower revenue in the fourth quarter, despite achieving "record revenue" of nearly $3.7 billion. Net income fell to $747 million from $783 million last year. Earnings came in at $2.42 a share, below the $2.79 analysts had expected.

Regions Financial slid 2.6%. The parent company of Regions Bank parent reported net income of $534 million for the fourth quarter, flat over the prior year. Adjusted earnings of 57 cents a share missed the 61 cents Wall Street had forecast.

PNC Financial Services gained 3.8% after fourth-quarter earnings topped analysts' estimates, with the company citing loan growth and higher demand for its financial services.

J.B. Hunt Transport Services fell 1%. Fourth-quarter sales declined 2% as prices and volumes fell across different parts of the business. Shares may have gotten ahead of themselves -- a 50% rally over the past three months has left the stock trading at about 29 times expected earnings, up from about 20 times earnings before the run started.

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com and George Glover at george.glover@dowjones.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

January 16, 2026 16:18 ET (21:18 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10